Opinion|Videos|May 8, 2024
Limitations of Conventional Imaging for Assessing Renal Masses
Experts on kidney cancer review challenges associated with limitations of conventional imaging for assessing renal masses and how to potentially improve sensitivity and specificity.
Advertisement
Episodes in this series
Advertisement
Related to this article
Robert J. Motzer, MD, discusses the significance of the belzutifan plus lenvatinib approval, adverse event management with the combination, and the evolving role of HIF-2α inhibition in ccRCC.
The approval is supported by data from the phase 3 LITESPARK-011 trial.
Advertisement
Advertisement
Trending on Urology Times
1
John Sfakianos, MD, on integrating ctDNA into bladder cancer trials
2
AMA issues Category I CPT codes for implantable tibial neuromodulation in UUI
3
FDA updates in urology: September 2026
4
Enzalutamide plus salvage radiotherapy associated with improved PFS in high-risk BCR
5